Relevant Articles About NSCLC Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to conduct comprehensive genomic analysis of high-grade CFOS using SNP array and targeted NGS. The results showed that the high-grade CFOS exhibit complex genomic alterations, featuring RTK gene amplifications and frequent tumor...
KEY TAKEAWAYS The study aimed to report outcomes from a substantial series of IM treated with curative-intent proton therapy. The study's findings concluded proton therapy effectively treated IM with acceptable toxicity, representing a substantial patient cohort....
KEY TAKEAWAYS The study aimed to explore the lipidome's association with skin cancers and identify potential mediators. The study found a negative causal link between PC (17:0_18:2) and keratinocyte carcinomas, partly mediated by TWEAK. Research indicates a...
The NADIMII phase 2 trial aimed to analyze F. prausnitzii’s potential as a cancer preventative in patients with NSCLC. The results revealed that …
The MARIPOSA phase 3 trial aimed to assess post-progression safety and discuss nurses’ role in AE education. The results showed Ami+Laz’s promise as …
The phase 2 trial aimed to provide comprehensive safety data from the INSIGHT 2 study with extensive follow-up. Tepotinib + osimertinib showed good …
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for various hematological malignancies. Still, its remarkable efficacy is accompanied by unique adverse events that must be carefully managed. This comprehensive literature review …
Objectives: Breast cancer is the most diagnosed cancer in women, with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) being the predominant subtype. Sacituzumab govitecan (SG), a novel antibody-drug conjugate, has emerged as a promising …
Objectives: For many malignancies, hypofractionated radiotherapy (HFRT) is an accepted standard associated with decreased treatment time and costs. United States provider beliefs regarding HFRT likely impact its adoption but are poorly studied. We surveyed US-based …
Objective: This systematic review and meta-analysis aims to evaluate the efficacy and safety of bevacizumab in patients with ovarian cancer over a shorter and longer follow-up period. Methods: We searched Medline, Cochrane CENTRAL, Scopus, and Google …